Efficacy and safety of Nintedanib plus Docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study.
Authors
Gottfried, MBennouna, J
Bondarenko, I
Douillard, J
Heigener, D
Krzakowski, M
Mellemgaard, A
Novello, S
Orlov, S
Summers, Yvonne J
Von Pawel, J
Stöhr, J
Kaiser, R
Reck, M
Affiliation
Lung Cancer Unit, Meir Medical Center, 4428164, Kfar Saba, IsraelIssue Date
2017-08
Metadata
Show full item recordAbstract
Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) <9 months.Citation
Efficacy and safety of Nintedanib plus Docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study. 2017, 12 (4):475-485 Target OncolJournal
Targeted OncologyDOI
10.1007/s11523-017-0517-2PubMed ID
28702806Type
ArticleLanguage
enISSN
1776-260Xae974a485f413a2113503eed53cd6c53
10.1007/s11523-017-0517-2
Scopus Count
Collections
Related articles
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
- Authors: Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, LUME-Lung 1 Study Group
- Issue date: 2014 Feb
- Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
- Authors: Dhillon S
- Issue date: 2015 Jun
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
- Authors: Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebsch I, Palmer M, Reck M, LUME-Lung 1 Study Group
- Issue date: 2015 Feb
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
- Authors: Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH, LUME-Lung 2 Study group
- Issue date: 2016 Dec
- Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
- Authors: Reck M, Mellemgaard A, von Pawel J, Gottfried M, Bondarenko I, Cheng Y, Zarogoulidis K, Luft A, Bennouna J, Barrueco J, Aboshady H, Hocke J, Kaiser R, Douillard JY, LUME-Lung 1 Study Group
- Issue date: 2015 Nov